Avidity Biosciences Inc [RNA] stock prices are down -3.44% to $14.04 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RNA shares have gain 3.77% over the last week, with a monthly amount glided 38.19%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, February 2024, Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2024, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,500 shares of its common stock and 37,750 restricted stock units (“RSUs”) to five (5) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the “2022 Inducement Plan”). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on May 22, 2023, when Evercore ISI upgraded its rating to a Outperform but kept the price target unchanged to $20 for it. Previously, Evercore ISI downgraded its rating to In-line on March 31, 2023, and kept the price target unchanged to $20. On July 20, 2022, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $29 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $29 on July 12, 2022. Evercore ISI initiated its recommendation with a Outperform and recommended $50 as its price target on September 07, 2021. Needham started tracking with a Buy rating for this stock on June 17, 2021, and assigned it a price target of $50.
The stock price of Avidity Biosciences Inc [RNA] has been fluctuating between $4.82 and $25.38 over the past year. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $14.04 at the most recent close of the market.
Analyzing the RNA fundamentals
The Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.14M for trailing twelve months, representing a surge of 13.54%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.66 points at the first support level, and at 13.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.50, and for the 2nd resistance point, it is at 14.95.
Avidity Biosciences Inc [RNA] reported earnings per share of -$0.71 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.77/share, meaning a difference of $0.06 and a surprise factor of 7.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.66 per share as compared to estimates of -$0.8 per share, a difference of $0.14 representing a surprise of 17.50%.
Ratios To Look Out For
It’s worth pointing out that Avidity Biosciences Inc [NASDAQ:RNA]’s Current Ratio is 11.40. In addition, the Quick Ratio stands at 11.40 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 102.60, the price to book ratio is 2.01.
Transactions by insiders
Recent insider trading involved Boyce Sarah, President and CEO, that happened on Jan 22 when 5092.0 shares were sold. CSTO, Flanagan W. Michael completed a deal on Jan 22 to sell 4129.0 shares. Meanwhile, Chief Human Resources Officer McCarthy Teresa sold 2065.0 shares on Jan 22.
